Notre offre FCPI Truffle InnoCroissance 2015 et Mandat de gestion

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


Pharnext is a Paris-based biopharmaceutical company founded in 2007 by an internationally renowned team led by Professor Daniel Cohen. Pharnext is focused on discovering, developing, and licensing pharmaceutical treatments for severe neurological diseases. The company’s drug repositioning approach involves identifying the common molecular targets between unrelated diseases and testing existing drugs on newly identified indications.

In 2009, Pharnext signed an exclusive R&D and marketing agreement with Ipsen for its Charcot Marie-Tooth disease drug program. Under the terms of the deal, Ipsen has an exclusive option on the drug program and also subscribed to the issue of convertible bonds. In the event it exercises its option at the end of a positive Phase II trial, Pharnext could be due cumulative development milestones of up to €91 million as well as double-digit royalties on net product sales.

Truffle Capital contributed to Pharnext’s founding in 2007, and is Pharnext’s majority shareholder.

Truffle board member: Dr. Philippe Pouletty